Elevation Oncology, Inc. (ELEV): Price and Financial Metrics
GET POWR RATINGS... FREE!
ELEV Stock Price Chart Interactive Chart >
ELEV Price/Volume Stats
| Current price | $3.03 | 52-week high | $16.22 |
| Prev. close | $3.35 | 52-week low | $2.28 |
| Day low | $2.92 | Volume | 462,800 |
| Day high | $3.40 | Avg. volume | 344,746 |
| 50-day MA | $2.89 | Dividend yield | N/A |
| 200-day MA | $5.80 | Market Cap | 70.46M |
Elevation Oncology, Inc. (ELEV) Company Bio
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically-defined patient populations in the United States. Its lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. The company was incorporated in 2019 and is based in New York, New York.
Latest ELEV News From Around the Web
Below are the latest news stories about Elevation Oncology Inc that investors may wish to consider to help them evaluate ELEV as an investment opportunity.
Elevation Oncology Highlights 2021 Achievements and Outlines Expected 2022 MilestonesElevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today highlighted its 2021 corporate achievements and outlined its expected milestones for 2022. Shawn M. Leland, PharmD, RPh, Founder and Chief Executive Officer, will present these corporate priorities on Wednesday, January 12, 2022, at 9:45 a.m. ET at the virtual 40th Annual J.P. Morgan Healthcare Conference. |
Elevation Oncology to Present at the H.C. Wainwright BIOCONNECT Virtual ConferenceElevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced that Shawn M. Leland, PharmD, RPh, Elevation Oncology's Founder and Chief Executive Officer, will participate in a pre-recorded fireside chat at the H.C. Wainwright BIOCONNECT Virtual Conference. |
Elevation Oncology to Present at the 40th Annual J.P. Morgan Healthcare ConferenceElevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced that Shawn M. Leland, PharmD, RPh, Elevation Oncology's Founder and Chief Executive Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 9:45 a.m. ET, in a virtual format. |
H.C. Wainwright Thinks Elevation Oncology’s Stock is Going to RecoverIn a report released today, Michael King from H.C. Wainwright initiated coverage with a Buy rating on Elevation Oncology (ELEV – Research Report) and a price target of $12.00. The company's shares closed last Wednesday at $4.90, close to its 52-week low of $4.15. According to TipRanks.com, King is a 5-star analyst with an average return of 20.0% and a 50.6% success rate. King covers the Healthcare sector, focusing on stocks such as Sonnet BioTherapeutics Holdings, Intellia Therapeutics, and Werewolf Therapeutics. Elevation Oncology has an analyst consensus of Strong Buy, with a price target consensus of $17.67. |
Elevation Oncology, Inc.s (NASDAQ:ELEV) Lock-Up Period Set To Expire on December 22ndElevation Oncologys (NASDAQ:ELEV) lock-up period will expire on Wednesday, December 22nd. Elevation Oncology had issued 6,250,000 shares in its IPO on June 25th. The total size of the offering was $100,000,000 based on an initial share price of $16.00. Shares of the company owned by company insiders and major shareholders will be eligible for trade [] |
ELEV Price Returns
| 1-mo | -5.61% |
| 3-mo | -11.14% |
| 6-mo | -54.84% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -49.67% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...